Has Philip Chang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $32,386 in general payments to Philip Chang, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Philip Chang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Philip Chang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Philip Chang, MD

Surgery · New York, NYNPI 1134375512

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,217 of the $32,386 with a category attached, or 74.8%. 15 manufacturers reported payments, led by Polynovo North America LLC at 50.9% of the total. 2025 is the largest year on record at $14,615, more than ten times the $464 reported in 2019. Among surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,386in general payments, 2019–2025

Across 73 payments — averaging $443.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Polynovo North America LLC$16K
Mallinckrodt Hospital Products Inc.$6K
Vericel Corporation$5K
Avita Medical Americas, LLC$3K
Smith+Nephew$393
Integra Lifesciences Corporation$322
plus $643 from 9 others

$60,358in research payments, 2019–2025

Across 24 payments — averaging $2514.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Polynovo North America LLC$60K

What the payments were for

Consulting fees$24,21775%
Speaking & faculty fees$6002%
Travel & lodging$2,8689%
Food & beverage$4,70115%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Polynovo North America LLC	35	$16,495
Mallinckrodt Hospital Products Inc.	2	$5,755
Vericel Corporation	5	$5,479
Avita Medical Americas, LLC	11	$3,299
Smith+Nephew	7	$393
Integra Lifesciences Corporation	1	$322
Urgo Medical North America, LLC	1	$207
Baxter Healthcare	2	$173
Teleflex LLC	3	$92
Lifenet Health	1	$55
Access Pro Medical, LLC	1	$34
Acell, Inc.	1	$26
Solventum Corporation	1	$22
Bioventus LLC	1	$21
Merck	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Novosorb BTM$15,608
STRATAGRAFT$5,755
NexoBrid$4,696
RECELL$2,627
INTEGRA$965
Epicel$757
PERMEADERM$410
Cohealyx$410
INTEGRA DERMAL REGENERATION TEMPLATE$322
PRIMATRIX$322
ACTICOAT 4" X 4"$253
Oasis$253
COLLAGENASE SANTYL$253
Versajet$253
VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$207
DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$207
UrgoK2$207
OSTENE$119

How this compares

$32,386 in reported general payments places this provider in the 90th percentile of 1,596 surgery providers in New York.

See all surgery providers in New York →

Medicare billing

Part B allowed, 2024

$65,673

Medicare patients

Services billed

504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	12	$108

Paid to pharmacies, not to this prescriber.

Other surgery in New York

Cheguevara AfanehNew York$1.4M
Flavio Malcher Martins de OliveiraNew York$695K
Yuri NovitskyNew York$548K
Rasa ZarnegarNew York$478K
Tanuja DamaniNew York$459K
Rache SimmonsNew York$371K
Marina KurianNew York$328K
Megan JenkinsNew York$290K
Brian JacobNew York$225K
Robin BlackstoneNew York$174K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →